Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Petra Lutterbuese"'
Autor:
Peter A. Kiener, Peter Kufer, Patrick A. Baeuerle, Steve Coats, Michael S. Kinch, Elizabeth Bruckheimer, Bernd Schlereth, Petra Lutterbuese, Shannon Roff, Ralf Lutterbuese, Scott A. Hammond
Supplementary Video 4E and F from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87ff43afd7719579e8bf5feb86d176bf
https://doi.org/10.1158/0008-5472.22368474.v1
https://doi.org/10.1158/0008-5472.22368474.v1
Autor:
Peter A. Kiener, Peter Kufer, Patrick A. Baeuerle, Steve Coats, Michael S. Kinch, Elizabeth Bruckheimer, Bernd Schlereth, Petra Lutterbuese, Shannon Roff, Ralf Lutterbuese, Scott A. Hammond
Supplementary Video 4I from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52902e6df683fe3dd79dcd5f71090458
https://doi.org/10.1158/0008-5472.22368459
https://doi.org/10.1158/0008-5472.22368459
Autor:
Peter A. Kiener, Peter Kufer, Patrick A. Baeuerle, Steve Coats, Michael S. Kinch, Elizabeth Bruckheimer, Bernd Schlereth, Petra Lutterbuese, Shannon Roff, Ralf Lutterbuese, Scott A. Hammond
The EphA2 receptor tyrosine kinase is frequently overexpressed and functionally altered in malignant cells and thus provides opportunities for selective targeting of tumor cells. We describe here the development of a novel, bispecific single-chain an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c189f7613093524823cf07cbcace9bc
https://doi.org/10.1158/0008-5472.c.6495966
https://doi.org/10.1158/0008-5472.c.6495966
Autor:
Peter A. Kiener, Peter Kufer, Patrick A. Baeuerle, Steve Coats, Michael S. Kinch, Elizabeth Bruckheimer, Bernd Schlereth, Petra Lutterbuese, Shannon Roff, Ralf Lutterbuese, Scott A. Hammond
Supplementary Video 4A and B from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cb96db4aacf3d3bf4abfc764fa4edac
https://doi.org/10.1158/0008-5472.22368495
https://doi.org/10.1158/0008-5472.22368495
Autor:
Peter A. Kiener, Peter Kufer, Patrick A. Baeuerle, Steve Coats, Michael S. Kinch, Elizabeth Bruckheimer, Bernd Schlereth, Petra Lutterbuese, Shannon Roff, Ralf Lutterbuese, Scott A. Hammond
Supplementary Video 4G and H from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::243a483eab733bc03468e9813b5dab59
https://doi.org/10.1158/0008-5472.22368468
https://doi.org/10.1158/0008-5472.22368468
Autor:
Peter A. Kiener, Peter Kufer, Patrick A. Baeuerle, Steve Coats, Michael S. Kinch, Elizabeth Bruckheimer, Bernd Schlereth, Petra Lutterbuese, Shannon Roff, Ralf Lutterbuese, Scott A. Hammond
Supplementary Video 4C and D from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99b7fad0a46861d98df25ecf43a5310a
https://doi.org/10.1158/0008-5472.22368483.v1
https://doi.org/10.1158/0008-5472.22368483.v1
Autor:
Benno Rattel, Anja Henn, Tobias Raum, Shyun Li, Julie M. Bailis, Michael C. Boyle, Virginie Naegele, Alexander Sternjak, Angela Coxon, Joachim Wahl, Christoph Dahlhoff, Oliver Thomas, Petra Lutterbuese, Kathrin Locher, John M. Harrold
Publikováno v:
Cancer Research. 80:3364-3364
Advanced gastric cancer remains a disease of high unmet medical need. In the United States, most patients present with symptomatic, incurable disease and prognosis is poor, with a 5-year survival rate of less than 10%. BiTE® (bispecific T cell engag
Autor:
Eva Vieser, Bernd Schlereth, Roman Kischel, Matthias G. Friedrich, Klaus Brischwein, Patrick A. Baeuerle, Maria Amann, Petra Lutterbuese, Peter Kufer, Grit Lorenczewski, Laetitia Petersen
Publikováno v:
Cancer Immunology, Immunotherapy. 58:95-109
MuS110 is a BiTE antibody bispecific for murine EpCAM (CD326) and murine CD3. A recent study has shown that microS110 has significant anti tumor activity at well-tolerated doses as low as 5 microg/kg in orthotopic breast and lung cancer models (Amann
Autor:
Bernd Schlereth, Sandrine Crommer, Antonio J. da Silva, Robert Hofmeister, Grit Lorenczewski, Mathias Locher, Laetitia Petersen, Klaus Brischwein, Patrick A. Baeuerle, Sandra Lippold, Petra Lutterbuese
Publikováno v:
Cancer Immunology, Immunotherapy. 56:459-468
An important mode of action shared by human IgG1 antibody therapies is antibody-dependent cellular cytotoxicity (ADCC). ADCC relies on the interaction of the antibody's Fc portion with Fc-gama receptors (FcgammaR) on immune effector cells. The anti-t
Autor:
Ralf Lutterbuese, Patrick A. Baeuerle, Petra Lutterbuese, Kathy Mulgrew, Peter Kufer, Peter A. Kiener, Bernd Schlereth, Evelyne Schaller, Scott A. Hammond, Michael Oberst, Doris Rau, Tobias Raum, Petra Meier, Susanne Mangold, Roman Kischel
Publikováno v:
Journal of immunotherapy (Hagerstown, Md. : 1997). 32(4)
Carcinoembryonic antigen (CEA, CD66e) is a well-characterized tumor-associated antigen that is frequently overexpressed in tumors. Phospholipases release CEA from tumor cells resulting in high circulating serum levels of soluble CEA (sCEA) that has b